KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Payables (2016 - 2025)

Biogen (BIIB) has 17 years of Payables data on record, last reported at $432.0 million in Q4 2025.

  • For Q4 2025, Payables fell 80.12% year-over-year to $432.0 million; the TTM value through Dec 2025 reached $432.0 million, down 80.12%, while the annual FY2025 figure was $432.0 million, 80.12% down from the prior year.
  • Payables reached $432.0 million in Q4 2025 per BIIB's latest filing, up from $413.1 million in the prior quarter.
  • Across five years, Payables topped out at $7.7 billion in Q2 2022 and bottomed at $354.5 million in Q2 2024.
  • Average Payables over 5 years is $2.2 billion, with a median of $1.2 billion recorded in 2022.
  • Peak YoY movement for Payables: surged 1954.89% in 2022, then plummeted 94.22% in 2023.
  • A 5-year view of Payables shows it stood at $1.6 billion in 2021, then soared by 326.4% to $6.8 billion in 2022, then plummeted by 91.83% to $553.3 million in 2023, then skyrocketed by 292.7% to $2.2 billion in 2024, then crashed by 80.12% to $432.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $432.0 million in Q4 2025, $413.1 million in Q3 2025, and $408.4 million in Q2 2025.